People: Cyberonics Inc (CYBX.OQ)

CYBX.OQ on NASDAQ Stock Exchange Global Select Market

52.97USD
17 Sep 2014
Price Change (% chg)

$-0.57 (-1.06%)
Prev Close
$53.54
Open
$53.50
Day's High
$53.54
Day's Low
$52.76
Volume
77,396
Avg. Vol
82,850
52-wk High
$73.48
52-wk Low
$49.69

Search Stocks

Summary

Name Age Since Current Position

Hugh Morrison

66 2010 Non-Executive Independent Chairman of the Board

Daniel Moore

53 2007 President, Chief Executive Officer, Director

Gregory Browne

61 2011 Chief Financial Officer, Senior Vice President - Finance

Rohan Hoare

49 2014 Chief Operating Officer, Senior Vice President

David Wise

59 2011 Senior Vice President, Chief Administrative Officer, Secretary

Milton Morris

44 2012 Senior Vice President - Research & Development

Randal Simpson

54 2009 Vice President - Operations

Darren Alch

48 2013 Vice President, General Counsel, Assistant Secretary

Mark Verratti

46 2011 Vice President - Global Sales

Bruce KenKnight

53 2013 Vice President - Emerging Therapy

Bryan Olin

47 2011 Vice President - Clinical , Quality & Regulatory

Sherrie Perkins

60 Vice President - Marketing & New Business Development

O'Neill D'Cruz

2014 Chief Medical Officer

Guy Jackson

72 2003 Independent Director

Joseph Laptewicz

65 2008 Independent Director

Alfred Novak

66 2007 Independent Director

Arthur Rosenthal

67 2007 Independent Director

Jon Tremmel

68 2010 Independent Director

Biographies

Name Description

Hugh Morrison

Mr. Hugh M. Morrison is Non-Executive Independent Chairman of the Board of Cyberonics, Inc. From July 2012 to present, Mr. Morrison has engaged in independent consulting and investments. From September 2008 through June 2012, he was a Managing Director at Callahan Advisors, LLC, an investment management company. From 1983 to December 2005, Mr. Morrison served as a director, and from January 1998 to December 2005 as chairman of the board of directors, of Advanced Neuromodulation Systems, Inc., a publicly-held designer, developer, manufacturer, and marketer of advanced implantable neurostimulation devices acquired by St. Jude Medical, Inc. in 2005. Mr. Morrison served as a director of Owen Healthcare, Inc., a publicly held hospital pharmacy management firm, from 1994 until it was acquired in 1996 by Cardinal Healthcare. In addition, Mr. Morrison served as a director of Dow Hickam Pharmaceuticals, Inc., a pharmaceutical manufacturer and marketer, from 1984 to 1991, when the company was sold to Mylan Laboratories, Inc. From March 1996 to May 2006, Mr. Morrison served as President and CEO, and from January 1998 to May 2006 as Chairman of the board of directors, of Pilgrim Cleaners, Inc., a retail dry cleaning company operating over 100 stores (“Pilgrim”), and its parent, Clean Acquisition, Inc. (“Clean”). In January 2004, Pilgrim and Clean each filed a petition under Chapter 11 of the Bankruptcy Code with the United States Bankruptcy Court for the Southern District of Texas, Houston Division. Subsequent to Mr. Morrison’s resignation, Pilgrim and Clean each filed a petition under Chapter 7 of the Bankruptcy Code with the United States Bankruptcy Court for the Southern District of Texas, Houston Division in July 2006. Mr. Morrison is licensed as a Certified Public Accountant.

Daniel Moore

Mr. Daniel J. Moore is President, Chief Executive Officer, Director of Cyberonics Inc., since May 1, 2007. Mr. Moore joined from Boston Scientific Corporation (“Boston Scientific”), a diverse maker of minimally invasive medical products, where, since 1989, he held positions in sales, marketing, and senior management in the United States and in Europe. His last position at Boston Scientific was President, International Distributor Management. Prior to that role, he held the position of President, Inter-Continental, the fourth largest business unit of Boston Scientific, with more than 1,000 global employees and revenues exceeding $700 million. Mr. Moore previously held senior management positions at several Boston Scientific U.S. and international divisions. He currently serves as a member of the board of directors for the Epilepsy Foundation of America, the Epilepsy Foundation of Texas (immediate past-Chair), the Epilepsy Foundation of Texas-Houston (immediate past-President), as chairman of the board of directors for the Medical Device Manufacturers Association, and as a member of the boards or advisory boards for BioHouston, Inc., the Medical Device Innovation Consortium, and the Weldon School of Biomedical Engineering at Purdue University. He also serves on the boards of two private companies, TriVascular, Inc., a privately-held medical technology company providing device solutions for endovascular aortic repair, and BrainScope, Company, Inc., a privately-held medical technology company focused on traumatic brain injury.

Gregory Browne

Mr. Gregory H. Browne is Chief Financial Officer, Senior Vice President - Finance of Cyberonics, Inc. Mr. Browne joined in July 2007 as Vice President, Finance & CFO. In April 2011, he was promoted to Senior Vice President, Finance & CFO. Mr. Browne has served as both CEO and CFO for several publicly traded healthcare companies. From May 2002 to June 2006, he was CFO at Amedisys, Inc., a home nursing company with revenues in excess of $600 million, during a period of substantial growth in revenue, profitability and market capitalization. From June 2006 to November 2006, Mr. Browne was a private investor, and from November 2006 to July 2007, he was a partner with Tatum, LLC, an executive services company. Since 2010, Mr. Browne has served as a director and member of the Compensation Committee of WCS Corporation, LLC, a privately-held company focused on wound care solutions. He was the founder in 1996 and served as President until March 2001 and a director until October 2001 of PeopleWorks, Inc., a human resource outsourcing company. PeopleWorks filed a petition for reorganization under chapter 11 of the Bankruptcy Code in November 2001. PeopleWorks’s petition was converted to chapter 7, and the company was liquidated in 2002. From January 1992 to July 1995, he served as CEO for Ramsay Healthcare Inc., a provider of psychiatric services, and from 1989 to 1991 as CEO for Ramsay-HMO, Inc., a health maintenance organization.

Rohan Hoare

Dr. Rohan H. Hoare, Ph.D., has been appointed as Chief Operating Officer, Senior Vice President of Cyberonics, Inc., with effect from April 28, 2014. Since joining Cyberonics in September 2013, Dr. Hoare has served as Senior Vice President, Strategic Planning, leading the company's business strategy development and execution. Formerly, he served as President of St. Jude Medical's Neuromodulation Division, which designs, manufactures and sells neuromodulation devices for the treatment of chronic pain, movement disorders and chronic migraine headache. He began his career with McKinsey & Co., a premiere strategy consulting firm, where he served clients in high tech, med tech and healthcare payor and providers for nearly a decade. Dr. Hoare received a Bachelor of Science in Physics and was awarded Faculty of Science Scholar honors at Monash University, Melbourne, Australia. He continued his studies at Harvard University as a Fulbright Scholar where he received a Master of Arts and a Ph.D. in Physics.

David Wise

Mr. David S. Wise is Senior Vice President, Chief Administrative Officer, Secretary of Cyberonics Inc. Mr. Wise joined in September 2003 as Vice President and General Counsel. He was appointed our Secretary in November 2003. In June 2009, he assumed responsibility for Human Resources and in April 2011, he was promoted to Senior Vice President & Chief Administrative Officer, as well as Secretary, with responsibility for Human Resources, Information Technology, Legal and Government Affairs. From 1994 to 2003, he was employed in positions of increasing responsibility at Centerpulse USA, Inc. (formerly Sulzer Medica), at the time a diverse global medical devices company, where he eventually served as Group Vice President and General Counsel. Prior to Centerpulse, he spent 12 years in private practice, focused on intellectual property and commercial litigation. Mr. Wise currently serves as a member of the board of directors of the Epilepsy Foundation of Texas and of the Epilepsy Foundation of Texas-Houston, where he also serves as Secretary.

Milton Morris

Dr. Milton Mayo Morris, Ph.D., is Senior Vice President - Research & Development of Cyberonics, Inc. Dr. Morris joined in January 2009 as Vice President, Research & Development and was promoted to Senior Vice President, Research & Development in June 2012. Before he joined us, Dr. Morris had been the Director, Program Management & Operations since July 2007 for Innerpulse Corporation, a private company developing an implantable defibrillator. Prior to Innerpulse, he spent 11 years at Boston Scientific and its predecessor, Guidant Corporation, where he served as Director, Marketing from May 2006 to July 2007, Field Clinical Representative from October 2004 to May 2006, Director, Research & Development from November 2002 to October 2004, and Manager, Research & Development from October 1999 to October 2002. Dr. Morris received his Ph.D. in Electrical Engineering from The University of Michigan and his Masters of Business Administration from the Kellogg School of Management at Northwestern University. He currently serves as a member of the advisory boards for the Purdue University School of Biomedical Engineering and the University of Houston Biomedical Engineering departments.

Randal Simpson

Mr. Randal L. Simpson is Vice President - Operations of Cyberonics Inc. Mr. Simpson joined in 1998 and served in various manufacturing management positions such as Director, Manufacturing, Director, Materials, and Sr. Director of Operations, until October 2003, when he became Vice President, Operations. From March 2006 until May 2008, Mr. Simpson was also responsible for the Quality Department, and from August 2007 until January 2009, he also assumed responsibility for the Research & Development Department. From February to May 2009, he again assumed responsibility for Quality. Prior to joining us, Mr. Simpson was employed by Intermedics, Inc., a manufacturer of implantable medical devices for cardiac rhythm management, including pacemakers and defibrillators, as Manager of Manufacturing. Mr. Simpson has nearly 30 years of manufacturing experience with 22 years of that time in the medical device industry.

Darren Alch

Mr. Darren W. Alch is Vice President, General Counsel, Assistant Secretary of Cyberonics Inc. Mr. Alch joined in August 2005 as Compliance Officer and Assistant General Counsel. He also assumed the role of Privacy Officer at that time. He was appointed Assistant Corporate Secretary in December 2010. In April 2011, he was appointed to the position of Vice President, Corporate Counsel & Compliance Officer and Assistant Secretary, and in April 2013, he was appointed to his current position as Vice President, General Counsel and Assistant Secretary. Before joining Cyberonics, he was a shareholder in the health law group of the national law firm of Jenkens & Gilchrist, P.C., which he joined in 1996. Prior to Jenkens & Gilchrist, he worked for pharmaceutical manufacturer Pfizer, Inc. in a sales and marketing capacity. Mr. Alch is a graduate of the U.S. Military Academy at West Point, and served on active duty in the U.S. Army as a field artillery officer.

Mark Verratti

Mr. Mark S. Verratti is Vice President - Global Sales of Cyberonics Inc. Mr. Verratti joined in March 2005 to help lead the sales force primarily in the United States and since that time has served in various sales management positions. In April 2011, he was promoted to Vice President, Sales – The Americas, Asia & EMMEA. In November 2011, he was promoted again to his current position, Vice President, Global Sales. Prior to March 2005, he held the position of Northeast Area Director for Forest Pharmaceuticals, managing more than 450 employees and revenues exceeding $500 million. Mr. Verratti has more than 18 years of sales and marketing experience in the pharmaceutical and medical device industry.

Bruce KenKnight

Dr. Bruce H. KenKnight, Ph.D., serves as Vice President - Emerging Therapy of Cyberonics, Inc. Most recently, Dr. KenKnight was President and CEO of Valtech Cardio Ltd, a privately-held company developing innovative solutions for surgical and percutaneous mitral valve repair and replacement. Prior to Valtech, he spent 20 years at Boston Scientific and its predecessor, Guidant Corporation, where he served as Vice President, Research and Business Development from September 2006 to January 2010, Director of Business Development from 2003 to 2006, Director of Research from 1999 to 2003, Manager of Research from 1996 to 1999 and Research Scientist from 1990 to 1996. Dr. KenKnight received his bachelors of science in Mechanical Engineering, masters of science degree and Ph.D. in Biomedical Engineering from the University of Minnesota. He currently serves as Chair of the industrial advisory board for the Department of Biomedical Engineering at the University of Minnesota.

Bryan Olin

Dr. Bryan D. Olin, Ph.D., is Vice President - Clinical , Quality & Regulatory of Cyberonics Inc. Dr. Olin joined in May 2009 as Vice President, Quality. In August 2009, he assumed additional responsibility for Clinical Affairs, and in April 2011, his responsibilities were expanded again to include Regulatory Affairs. Prior to May 2009, Dr. Olin was employed at Zeltiq Aesthetics, Inc., a privately-held medical technology company in the San Francisco area, where he had served as Sr. Director, Quality Assurance since October 2007. Prior to Zeltiq Aesthetics, Dr. Olin was employed at the LifeScan and Cordis companies of Johnson & Johnson from 1999 to 2007, holding several positions of increasing responsibility in quality assurance, statistics, and clinical data management. Dr. Olin began his career with Procter & Gamble in 1993 after obtaining his Ph.D. in Statistics from Iowa State University. He currently serves as our representative on the board of directors of Cerbomed GmbH, in whom we have made an investment. Cerbomed is a private medical device company that manufactures a transcutaneous vagus nerve stimulation device. He also serves on the board of directors for the Medical Devices Innovation Consortium and as an industry representative on the steering committee for The National Patient-Centered Clinical Research Network (PCORnet).

Sherrie Perkins

Mr. Sherrie L. Perkins is Vice President - Marketing & New Business Development of Cyberonics, Inc. Ms. Perkins joined us in August 2000 as Marketing Director to develop and lead the pre-launch and launch strategy for the depression indication, as well as the medical marketing strategy for the epilepsy indication. In 2008, she transitioned to a newly-created role in New Business Development and was named Vice President, Marketing & New Business Development in 2011. Prior to joining Cyberonics, Ms. Perkins held various leadership positions in sales, marketing and business development at Collagen Corp., a medical device company focused in the aesthetic dermatology and plastic surgery markets, and at Syva Company, a medical equipment and diagnostics company focused in the therapeutic drug monitoring market. Ms. Perkins currently serves as our representative on the board of directors of ImThera Medical, Inc., a private medical device company developing an implantable neurostimulation solution for obstructive sleep apnea, in whom we have made an investment.

O'Neill D'Cruz

Dr. O'Neill F. D'Cruz, M.D. is Chief Medical Officer of the Company. Dr. D'Cruz was most recently Medical Director, Neurology at UCB, S.A., and previously Professor of Neurology and Pediatrics at University of North Carolina-Chapel Hill. He also earned a Master of Business Administration at the Kenan-Flagler Business School, UNC-Chapel Hill. In addition to industry experience in clinical development, pharmacovigilance, regulatory interactions, public-private partnerships and business development, Dr. D'Cruz has worked in the field of epilepsy for over two decades, as a board-certified neurologist and epileptologist, health policy and patient advocate, clinical investigator and consultant to leading pharmaceutical companies. Dr. D'Cruz was an investigator in Cyberonics' E-05 study, the pivotal study used to obtain the company's original PMA approval for the VNS Therapy® System in 1997, as well as in clinical studies of most of the currently-marketed second-generation anti-epileptic drugs.

Guy Jackson

Mr. Guy C. Jackson is Independent Director of Cyberonics Inc., since July 8, 2003. In June 2003, Mr. Jackson retired from the accounting firm of Ernst & Young LLP after 35 years with the firm and one of its predecessors, Arthur Young & Company. During his career, Mr. Jackson served as the audit partner for a number of public companies. Mr. Jackson has a B.S. degree from The Pennsylvania State University and a M.B.A. from the Harvard Business School. Mr. Jackson also serves on the board of directors and is chairman of the audit committees of Digi International, Inc., a technology company, and Life Time Fitness, Inc., an operator of health and activity centers, and is a former director and chairman of the audit committees of Urologix, Inc., a medical device company, and EpiCept Corporation, a specialty pharmaceutical company, which merged with Immune Pharmaceuticals Inc. Mr. Jackson’s particular qualifications for service on Board include his understanding of audit committee and board processes, his substantial experience with external and internal audits, his expertise in the finance area, and his medical technology knowledge gained as a partner at Ernst & Young LLP and on other boards.

Joseph Laptewicz

Mr. Joseph E. Laptewicz, Jr., is Independent Director of Cyberonics Inc., since September 25, 2008. Mr. Laptewicz, who retired as a business executive in 2000, has extensive medical device experience. From 1998 to 2005, he served on the board of directors of Advanced Neuromodulation Systems, Inc., a publicly-held manufacturer of implantable neuromodulation devices for the treatment of pain acquired by St. Jude Medical, Inc. in 2005. From 1996 to 2003, he served on the board of directors of AngioDynamics, Inc., a publicly-held manufacturer of interventional radiology products. From 1994 to 2000, Mr. Laptewicz served as President and CEO, and from 2001 to 2004 as Chairman of the board of directors, of Empi, Inc., a leading manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. From 1972 to 1994, Mr. Laptewicz served in various positions of increasing responsibility for subsidiaries of Pfizer, Inc., at the time a large pharmaceutical and medical technology company, including Vice President and General Manager from 1990 to 1991 and President from 1991 to 1994 of Schneider (USA), Inc., a worldwide manufacturer of catheters, stents, and related medical products. Mr. Laptewicz’s particular qualifications for service on our Board include many years of demonstrated managerial ability from service as CEO and President and in other senior executive positions at medical technology companies and his experience serving on the board of directors of Advanced Neuromodulation Systems, Inc.

Alfred Novak

Mr. Alfred J. Novak is Independent Director of Cyberonics Inc. Since April 2014, Mr. Novak has been engaged as President and CEO of Syntheon Cardiology, LLC, an early-stage company developing a percutaneous prosthetic aortic heart valve. Since September 1999, he has served on the board of directors of OrbusNeich Medical Technology Company, Ltd., a privately-held interventional cardiology company, where he was Chairman and CEO from January 2010 until October 2013. He previously served as Chairman of the board of directors of ProRhythm, Inc., a privately-held company dedicated to the treatment of atrial fibrillation through the use of ultrasound technologies. In September 1998, he was a founder of Syntheon, LLC, a privately-held company that focused on minimally invasive medical devices for the gastroenterology and vascular markets. From October 2002 until March 2006, Mr. Novak was the President, CEO and a director of Novoste Corporation, a publicly-held interventional cardiology company. From December 1998 until October 2002, Mr. Novak was a member of the board of directors of Sutura, Inc., a vascular closure company. Mr. Novak was President, CEO, and a director of Biosense, Inc., an electrophysiology company, from July 1996 until January 1998 when it was acquired by Johnson & Johnson.

Arthur Rosenthal

Dr. Arthur L. Rosenthal, Ph.D., is Independent Director of Cyberonics Inc., since January 29, 2007. Since April 2012, he has been a co-founder and the CEO of gEyeCue Medical Systems, Ltd., a development-stage company headquartered in Galway, Ireland developing intelligent biopsy systems, and since June 2011, he has been a medical technology consultant. From June 2009 until June 2011, he served as President and CEO of Cappella, Inc., a development-stage company focused on novel device solutions for coronary artery disease, where he continued as Executive Vice Chairman until July 2012. Dr. Rosenthal served as chairman, from January 2002, and CEO, commencing in January 2005, of Labcoat, Ltd. From January 1994 to May 2000, he was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston Scientific, and from May 2000 until his retirement in January 2005, he was a Senior Vice President, Chief Scientific Officer, and Executive Committee Member of Boston Scientific. From 2000 until 2010, Dr. Rosenthal served as a non-executive director, and from 2006 until 2010, as chairman of the Remuneration Committee, of Renovo, Ltd., a U.K.-based pharmaceutical company that became publicly traded in 2006. In July 2009, Dr. Rosenthal joined the board of Interface Biologics, Inc. In April 2011, he was elected Chairman at Interface Biologics, Inc. and joined the board of Arch Therapeutics, Inc. (OTCQB:ARTH), a life science company based in Natick, MA developing liquid polymers to stop or control bleeding. From June 2011 until May 2013, he served as a non-executive director on the board of Tornado Medical Systems Inc., an early-stage medical imaging and spectroscopy company based in Toronto. Currently, he holds the position of Professor of Practice in Biomedical Engineering at the College of Engineering at Boston University and also as Enterprise Ireland’s Lifesciences Start-Up Ambassador for the United States.

Jon Tremmel

Mr. Jon T. Tremmel is Independent Director of Cyberonics Inc., since September 23, 2010. He has been a business consultant since his retirement from Medtronic, Inc. in April 2007, where he had been the President of Medtronic’s Neurological Division since March 2003 and President of Medtronic’s Physio-Control Division from May 2001 until March 2003. Mr. Tremmel also served as the President of Medtronic’s Tachyarrhythmia Management and Interventional Vascular Divisions between 1992 and 2001. Prior to 1992, he served in various positions of increasing responsibility at Medtronic after joining the company in 1978. Mr. Tremmel currently serves on the board of directors and compensation committee of EnteroMedics, Inc., a publicly-traded company that has developed a neurostimulation device for the treatment of obesity, ACell Inc., a privately-held company developing products for the treatment of regenerative and tissue repair applications in wounds, and Flowonix Medical Incorporated, a privately-held company developing implantable drug pump technology for pain and other indications.

Basic Compensation

Options Compensation

Name Options Value

Hugh Morrison

0 0

Daniel Moore

48,000 1,770,010

Gregory Browne

21,642 701,055

Rohan Hoare

0 0

David Wise

231,561 2,334,365

Milton Morris

15,000 512,179

Randal Simpson

4,750 97,418

Darren Alch

0 0

Mark Verratti

0 0

Bruce KenKnight

0 0

Bryan Olin

0 0

Sherrie Perkins

0 0

O'Neill D'Cruz

0 0

Guy Jackson

0 0

Joseph Laptewicz

0 0

Alfred Novak

0 0

Arthur Rosenthal

0 0

Jon Tremmel

0 0
Search Stocks